Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136957

Published: 2020

Journal Articles

Mitochondrial Spare Reserve Capacity : A New Predictive Metabolic Biomarker for Aggressiveness of Acute Myeloid Leukemia

Quentin Fovez, Bruno Quesnel, MD PhD, William Laine, Raeeka Khamari, Celine Berthon, MD PhD, Laure Goursaud, MD, Nicolas Germain, MD, Claude Preudhomme, MD PhD, Philippe Marchetti, MD PhD, Jérôme Kluza, PhD

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-139510

Published: 2020

Journal Articles

Antimetabolic Cooperativity with l-Asparaginase and Tyrosine Kinase Inhibitor Quizartinib to Eradicate Persistant FLT3-ITD Leukemic Cells

Quentin Fovez, Raeeka Khamari, Anne Trinh, PhD, William Laine, Bruno Quesnel, MD PhD, Philippe Marchetti, MD PhD, Jérôme Kluza, PhD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-139696

Published: 2020

Journal Articles

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Blood (2017) 130 (Supplement 1): 889.

https://doi.org/10.1182/blood.V130.Suppl_1.889.889

Published: 2017

Journal Articles

De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory

Loïc Renaud, Olivier Nibourel, PharmD, PhD, Celine Berthon, Christophe Roumier, Céline Rodriguez, Cecile Frimat, Catherine Roche-Lestienne, Aline Renneville, MD, Bruno Quesnel, MD PhD, Claude Preudhomme, MD PhD

Blood (2016) 128 (22): 4013.

https://doi.org/10.1182/blood.V128.22.4013.4013

Published: 2016

Journal Articles

Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group

Thomas Cluzeau, MDPhD, Orianne Wagner-Ballon, Thomas Boyer, Estelle Guerin, Emmanuel Benayoun, Daniel Lusina, Isabelle Garcia, Claude Gardin, Pierre Fenaux, MD PhD, Cecile Pautas, Bruno Quesnel, MD PhD, Dominique Bordessoule, Christine Terré, Xavier Thomas, MD PhD, Sylvie Castaigne, Aline Renneville, Claude Preudhomme, Herve Dombret, MD

Blood (2015) 126 (23): 2568.

https://doi.org/10.1182/blood.V126.23.2568.2568

Published: 2015

Journal Articles

Expanded Access Program of Graspa for Treatment of Patients with Acute Lymphoblastic Leukemia Unable to Receive Other Form of L-Asparaginase - a Status Update (NCT02197650)

Yves Bertrand, MDPhD, Hervé Dombret, Bruno Quesnel, MD PhD, Jean-Louis Stephan, MD, Claudine Schmitt, MD, Severine Lissandre, MD, Maryline Poiree, MD, Christian Recher, MDPhD, Emmanuel Plouvier, MD, Cécile Dumesnil de Maricourt, MD, David Salako, MSc, Yann Godfrin, PhD, Iman El Hariry, MDPhD

Blood (2015) 126 (23): 4877.

https://doi.org/10.1182/blood.V126.23.4877.4877

Published: 2015

Journal Articles

Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)

Blood (2014) 124 (21): 482.

https://doi.org/10.1182/blood.V124.21.482.482

Published: 2014

Journal Articles

Epidemiology of Adults AML in Nord-Pas De Calais and Picardy

Blood (2014) 124 (21): 2281.

https://doi.org/10.1182/blood.V124.21.2281.2281

Published: 2014

Journal Articles

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Blood (2014) 124 (21): 2327.

https://doi.org/10.1182/blood.V124.21.2327.2327

Published: 2014

Journal Articles

Multiclonal Diagnosis and MRD Follow-up in ALL with HTS Coupled with a Bioinformatic Analysis

Nathalie Grardel, Mikaël Salson, Aurélie Caillault, Marc Duez, Céline Villenet, Christophe Roumier, Martin Figeac, Brigitte Nelken, Bruno Quesnel, MD PhD, Claude Preudhomme, PharmD, PhD, Mathieu Giraud

Blood (2014) 124 (21): 1083.

https://doi.org/10.1182/blood.V124.21.1083.1083

Published: 2014

Journal Articles

Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group

Thomas Smol, Aline Renneville, Olivier Nibourel, Alice Marceau-Renaut, Karine Celli-Lebras, Céline Berthon, Bruno Quesnel, MD PhD, Nicolas Boissel, MD PhD, Christine Terré, Xavier Thomas, Sylvie Castaigne, Hervé Dombret, MD PhD, Claude Preudhomme, PharmD, PhD

Blood (2014) 124 (21): 1062.

https://doi.org/10.1182/blood.V124.21.1062.1062

Published: 2014

Journal Articles

Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study

Blood (2013) 122 (21): 2753.

https://doi.org/10.1182/blood.V122.21.2753.2753

Published: 2013

Journal Articles

AML At First Relapse: A Real Life Picture

Eileen Mary Boyle, MD, Claude Preudhomme, MD, PhD, Olivier Nibourel, Catherine Roche-Lestienne, PhD, Gareth J Morgan, MD PhD, Brigitte Dupriez, MD, Isabelle Plantier, MD, Berengere Gruson, MD, Jean Pierre Marolleau, MD, PhD, Delphine Lebon, MD, Jose Fernandes, MD, Christophe Willekens, Bruno Quesnel, MD, PhD, Céline Berthon, MD, PhD

Blood (2013) 122 (21): 3895.

https://doi.org/10.1182/blood.V122.21.3895.3895

Published: 2013

Journal Articles

The B7-H3 Protein In Acute Myeloid Leukemia

Thomas Guéry, MD, Christophe Roumier, MD, Céline Berthon, MD, PhD, Pascale Lepelley, MD, Aline Renneville, MD, PhD, Olivier Nibourel, Florent Dumezy, MD, Valérie Soenen, MD, PhD, Catherine Roche, PhD, Claude Preudhomme, MD, PhD, Bruno Quesnel, MD, PhD

Blood (2013) 122 (21): 2620.

https://doi.org/10.1182/blood.V122.21.2620.2620

Published: 2013

Journal Articles

Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL– Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group

Blood (2013) 122 (21): 495.

https://doi.org/10.1182/blood.V122.21.495.495

Published: 2013

Journal Articles

Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM)

Stephanie Poulain, Christophe Roumier, Charles Herbaux, MD, Aline Renneville, MD, Elisabeth Bertrand, Agnes Daudignon, Sabine Tricot, MD, Valérie Soenen, Catherine Roche-Lestienne, Olivier Nibourel, Bruno Quesnel, MD, PhD, Claude Preudhomme, Patrick Duthilleul, Xavier Leleu, MD

Blood (2012) 120 (21): 297.

https://doi.org/10.1182/blood.V120.21.297.297

Published: 2012

Journal Articles

B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenström Macroglobulinemia

Charles Herbaux, MD, Guillemette Marot, Elisabeth Bertrand, Natacha Broucqsault, Sylvie Zouitna-Galiègue, Christophe Roumier, Nicolas Poret, Valérie Soenen, Olivier Nibourel, Catherine Roche-Lestienne, Aline Renneville, Eileen Boyle, Guillemette Fouquet, MD, Sabine Tricot, MD, Claude Preudhomme, Bruno Quesnel, MD, PhD, Stephanie Poulain, Xavier Leleu, MD, PhD

Blood (2012) 120 (21): 1288.

https://doi.org/10.1182/blood.V120.21.1288.1288

Published: 2012

Journal Articles

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Lionel Ades, MD, PhD, Mathilde Lamarque, MD, Sophie Raynaud, Raphael Itzykson, Sylvain Thepot, Bruno Quesnel, MD, PhD, Francois Dreyfus, Odile Beyne Rauzy, MD, PhD, Pascal Turlure, MD, Norbert Vey, MD, Christian Recher, MD, Caroline Dartigeas, MD, Laurence Legros, MD, PhD, Jacques Delaunay, MD, Sorin Visanica, Aspasia Stamatoullas, Pierre Fenaux, MD, PhD

Blood (2012) 120 (21): 422.

https://doi.org/10.1182/blood.V120.21.422.422

Published: 2012

Journal Articles

Metabolites of Tryptophan Catabolism Are Elevated in Sera of Patients with Myelodysplastic Syndromes and Inhibit Hematopoietic Progenitor Amplification

Céline Berthon, MD, PhD, Michaela Fontenay, MD, PhD, Selim Corm, MD, PhD, Isabelle Briche, Michel Lhermitte, MD, PhD, Bruno Quesnel, MD, PhD

Blood (2012) 120 (21): 3843.

https://doi.org/10.1182/blood.V120.21.3843.3843

Published: 2012

NARROW

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Mitochondrial Spare Reserve Capacity : A New Predictive Metabolic Biomarker for Aggressiveness of Acute Myeloid Leukemia

Antimetabolic Cooperativity with l-Asparaginase and Tyrosine Kinase Inhibitor Quizartinib to Eradicate Persistant FLT3-ITD Leukemic Cells

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory

Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group

Expanded Access Program of Graspa for Treatment of Patients with Acute Lymphoblastic Leukemia Unable to Receive Other Form of L-Asparaginase - a Status Update (NCT02197650)

Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)

Epidemiology of Adults AML in Nord-Pas De Calais and Picardy

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Multiclonal Diagnosis and MRD Follow-up in ALL with HTS Coupled with a Bioinformatic Analysis

Absolute Quantification of EVI1 Overexpression in Acute Myeloid Leukemia By RQ-PCR Analysis : A Study of the ALFA Group

Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study

AML At First Relapse: A Real Life Picture

The B7-H3 Protein In Acute Myeloid Leukemia

Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL– Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group

Genome Wide SNP Array (SNPa) Analysis Reveals Clonal Evolution During Clinical Course in Waldenstrom's Macroglobulinemia (WM)

B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenström Macroglobulinemia

Revised-IPSS (IPSS-R) Is a Powerful Tool to Evaluate the Outcome of MDS Patient Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience

Metabolites of Tryptophan Catabolism Are Elevated in Sera of Patients with Myelodysplastic Syndromes and Inhibit Hematopoietic Progenitor Amplification

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only